Edwin L. Parsley

Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX.

Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.

Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.

Aires Pharmaceuticals, Inc. develops drugs to treat pulmonary disorders. It offers Aironite, an inhaled drug that is used to treat adult and pediatric pulmonary hypertension, cystic fibrosis, pneumonia and other respiratory infections. The company was founded by Wendy S. Johnson in 2006 and is headquartered in San Diego, CA.

Part of CSL Ltd., Seqirus GmbH is a German company that develops and produces flu vaccines. The company is based in Marburg, Germany. The CEOs are Sanat Jeetun, Frank Eberlein. The company was founded in 2002.

Respira Therapeutics, Inc. engages in provision of pulmonary delivery of therapeutics for respiratory diseases. Its technology Dry Powder Inhaler (DPI), deliver dry powder drug products to the lung more effectively than other DPI technologies. The company was founded in 2010 and is headquartered in Albuquerque, NM.